MedPath

ChromaDex

ChromaDex logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1999-01-01
Employees
106
Market Cap
$265M
Website
http://www.chromadex.com
Introduction

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults

Not Applicable
Completed
Conditions
Mood
Cognitive Function
Sleep
Interventions
Dietary Supplement: 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
Dietary Supplement: Placebo
Dietary Supplement: 300 mg/day of TRU NIAGEN (nicotinamide riboside)
First Posted Date
2018-06-19
Last Posted Date
2019-07-24
Lead Sponsor
ChromaDex, Inc.
Target Recruit Count
40
Registration Number
NCT03562468
Locations
🇺🇸

MB Clinical Research, Boca Raton, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath